

Takeda announces liquidation of holding company

22 January 2020 | News

All investments in subsidiaries owned by Shire Pharmaceutical Holdings Ireland Limited upon entering into liquidation will be transferred to and retained under direct ownership of Takeda



Takeda Pharmaceutical Company Limited, headquartered in Japan, is a value-based research-driven biopharmaceutical leader dedicated to bringing Better Health and a Brighter Future to patients by translating the science into highly innovative medicines. Takeda's research and development work focuses on four major therapeutic areas: oncology, rare diseases, neuroscience, and gastroenterology (GI).

Takeda has announced it intends to liquidate its fully owned Irish company Shire Pharmaceutical Holdings Ireland Limited. All investments in subsidiaries owned by Shire Pharmaceutical Holdings Ireland Limited upon entering into liquidation will be transferred to and retained under direct ownership of Takeda Pharmaceutical Company Limited.

The liquidation of Shire Pharmaceutical Holdings Ireland Limited is part of a company-wide legal entity rationalization program, related to the integration of Shire, to help simplify the combined legal entity ownership structure and allow for more efficient income repatriation to Takeda.